To examine the utility of CRISPR-SADD as a generally applicable tool for pharmaceutical development, we selected additional leukemia therapeutic target proteins (DOT1L, MOF, and LSD1) (5, 42, 43) that their drug-protein binding has been previously defined by cocrystallization (44–46). This evidence concerns the gene KDM1A and leukemia.